GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Certara Inc (NAS:CERT) » Definitions » Tax Expense

Certara (Certara) Tax Expense : $-1.6 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Certara Tax Expense?

Certara's tax expense for the months ended in Mar. 2024 was $-0.8 Mil. Its tax expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.6 Mil.


Certara Tax Expense Historical Data

The historical data trend for Certara's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Certara Tax Expense Chart

Certara Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial -0.23 -0.78 9.89 4.02 0.21

Certara Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 3.68 -4.64 0.07 -0.75

Certara Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Certara  (NAS:CERT) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Certara Tax Expense Related Terms

Thank you for viewing the detailed overview of Certara's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Certara (Certara) Business Description

Traded in Other Exchanges
N/A
Address
100 Overlook Center, Suite 101, Princeton, NJ, USA, 08540
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA, and other regions, of which a majority of revenue is derived from the United States.
Executives
Richard M. Traynor officer: See Remarks 1114 AVENUE OF THE AMERICAS, 45TH FLOOR, NEW YORK NY 10036
Leif E Pedersen officer: President, Software 10188 TELESIS COURT, SUITE 100, SAN DIEGO CA 92121
Eran Broshy director C/O VENTIV HEALTH, 200 COTTONTAIL LN. VANTAGE COURT N., SOMERSET NJ 08873
Patrick F Smith officer: PRESIDENT, INTEGRATED DRUG DEV C/O CERTARA, INC., 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
John E Gallagher officer: CHIEF FINANCIAL OFFICER BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07417
Arsenal Saturn Holdings Lp 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Jeffrey B. Kovach 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii-b Lp 10 percent owner 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Terrence M. Mullen 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Eqt Avatar Parent L.p. 10 percent owner 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Arsenal Capital Investment Iii Lp 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Investment Vi Lp 10 percent owner C/O ARSENAL CAPITAL PARTNERS, 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
Arsenal Capital Partners Iii Lp 10 percent owner 100 PARK AVENUE, 31ST FLOOR, NEW YORK NY 10017
David Spaight director 100 OVERLOOK CENTER, SUITE 101, PRINCETON NJ 08540
Mason P Slaine director 2777 SUMMER STREET, SUITE 209, STAMFORD CT 06905